In their interim analysis of a 5-year open-label extension trial, study investigators evaluated the safety and tolerability of erenumab treatment in episodic migraine patients who completed ≥3 years of the trial or discontinued treatment.
DFN-02 nasal spray may be effective, well tolerated, and safe for the acute treatment of episodic migraine.
The antiepileptic drug levetiracetam may represent an effective prophylactic treatment option for episodic migraine.
Patients with chronic migraine exposed to visual stimulation may have enhanced activity in the spinal trigeminal nucleus and the right superior colliculus compared with healthy individuals.
Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.
A monthly subcutaneous injection of 70 mg erenumab may represent an effective prophylactic treatment for episodic migraine.
A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.
Pain experienced by patients during episodic migraine is associated with the occurrence of white matter hyperintensities in the cerebral hemisphere ipsilateral to the pain side.
Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.
Complete results from 2 phase 3 trials examining the effects of 2 humanized monoclonal antibodies in patients with episodic and chronic migraine were published simultaneously.
A large proportion of patients with episodic migraine have greater risk for cardiovascular disease with increasing age and subsequently have contraindications to treatment with triptan and ergot medications.
A recently published case series describes a new subtype of chronic daily headache that appears to be associated with elevated cerebrospinal fluid pressure.
Among individuals diagnosed with episodic migraines, stressful events can accurately predict an individual's risk of a headache, even before the onset of prodromal symptoms.
Examination of hypothalamic activity shows distinctly different patterns between episodic and chronic forms of migraine.
In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.
Frequent Headache, Depression, and Medication Overuse Have Negative Impact on Treatments for Episodic MigraineJune 10, 2016
Effectiveness of an Anti-CGRP Antibody in Enhancing Wellness During Migraines' Prodrome and Postdrome PhasesJune 10, 2016
Anti-CGRP Antibody for Migraine
Clinical Pain Advisor Articles
- Aetna-CVS Merger Approved
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Lower Weighting of Hand Cortical Representations in CRPS
- Predicting Success of Focal Nerve Surgery Based on Diagnostic Block Response
- Aetna-CVS Merger Approved
- FDA Announces Draft Guidance for Consumer OTC Access to Previously Prescription Drugs
- Maryland Legislature: Will Federal Courts Permit State Regulation of Drug Prices?